BREAKING: A Helicopter Carrying Iran's President Has Crashed
Former Ted Cruz Communications Director and CNN Commentator Alice Stewart Has Died
How Trump Reacted to a Dysfunctional Podium in Minnesota
What Caused Marjorie Taylor Green and Jasmine Crockett to Rip Into Each Other
Bill Maher Nails What's at the Heart of the Left's Outrage Over Harrison...
Whoever Edited This Clip About Biden Deserves Major Props...And Trump Certainly Noticed It
Washington Is High School With Paychecks
A Quick Bible Study Vol. 218: What the Bible Says About Brokenness
Catholic Groups Accuse Biden Admin of Withholding Funds From Hospitals Who Don't Perform...
MSNBC Legal Analyst Thinks Blaming Bob Menendez’s Wife Is a Good Tactic
Russia Warns U.S. Is 'Playing With Fire' in Its Continued Support for Ukraine
Good Teaching Requires the Right Ingredients
Trump Indictments Have Ignited a Juggernaut of a Presidential Campaign
Peru Moves To Treat Bizarre Delusions of Transgender Ideology
Colombian Illegal Alien Wanted for Homicide Captured in Massachusetts
Tipsheet

Pfizer CEO: Our Vaccines Offer ‘Limited, If Any Protection’

AP Photo/Pablo Martinez Monsivais, File

Speaking during remarks to a J.P. Morgan healthcare conference this week, Pfizer CEO Albert Bourla openly stated current vaccines the company developed for Wuhan coronavirus offer "limited, if any" protection against contracting current variants of the disease. He then encouraged booster shots. 

The statement from Bourla comes as the Biden administration continues to justify vaccine mandates for federal workers, contractors and private businesses. The Supreme Court heard arguments about President Biden's mandates for private companies and medical workers last week. A ruling is expected soon on the constitutionality of the mandates. 

A number of people who have pointed out the waning efficacy of Pfizer's vaccines, which Bourla touted last year as being "100 percent" effective against contracting or transmitting the virus, have been banned by social media companies. 

Meanwhile, Bourla also announced this week the company is developing a vaccine specific to Omicron. It is expected to be ready in March when health officials predict the latest wave of the mild variant will already be over. 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos